Cabot Wealth Management Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,290 shares of the company’s stock after purchasing an additional 124 shares during the quarter. Cabot Wealth Management Inc.’s holdings in Johnson & Johnson were worth $639,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in JNJ. Winslow Evans & Crocker Inc. increased its position in shares of Johnson & Johnson by 0.3% during the 2nd quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock worth $3,037,000 after purchasing an additional 69 shares in the last quarter. Lathrop Investment Management Corp grew its stake in Johnson & Johnson by 1.4% during the second quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock worth $689,000 after buying an additional 69 shares during the last quarter. Reik & CO. LLC increased its holdings in shares of Johnson & Johnson by 0.4% during the second quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock worth $2,493,000 after buying an additional 70 shares in the last quarter. Delta Investment Management LLC raised its stake in shares of Johnson & Johnson by 1.0% in the second quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock valued at $1,041,000 after acquiring an additional 71 shares during the last quarter. Finally, IFG Advisory LLC boosted its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. IFG Advisory LLC now owns 16,170 shares of the company’s stock worth $2,274,000 after acquiring an additional 71 shares in the last quarter. Institutional investors own 67.44% of the company’s stock.
JNJ stock opened at $150.85 on Tuesday. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The firm has a market cap of $397.12 billion, a PE ratio of 23.72, a P/E/G ratio of 3.04 and a beta of 0.69. The business’s 50-day moving average price is $145.39 and its two-hundred day moving average price is $146.58.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.01 dividend. This represents a $4.04 annualized dividend and a dividend yield of 2.68%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.54%.
JNJ has been the subject of a number of research analyst reports. Bank of America reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 20th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Independent Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the company from $161.00 to $164.00 in a report on Monday, July 20th. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Credit Suisse Group upped their target price on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $164.93.
In related news, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.27% of the stock is owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Story: NASDAQ
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.